Open Forum Infect Dis . Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report

[tetano]

Open Forum Infect Dis


. 2022 Sep 27;9(10):ofac499.
doi: 10.1093/ofid/ofac499. eCollection 2022 Oct.
Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report


Jennifer Chen Li ^{1 2} , Jonathan Siglin ^{2 3} , Michael S Marshall ^{2 4} , Anat Stemmer-Rachamimov ^{2 4} , Seth M Bloom ^{2 5 6} , Kimberly G Blumenthal ^{1 2 7}



Affiliations

• PMID: 36267257
• PMCID: PMC9578160
• DOI: 10.1093/ofid/ofac499

Abstract

Reported adverse reactions to the mRNA-1273 vaccine (Spikevax, Moderna Inc) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from mild, local delayed cutaneous reactions to rarer, more serious reactions such as myocarditis. Here, we describe the presentation and successful treatment of delayed, localized necrotizing inflammatory myositis following a third dose of the mRNA-1273 SARS-CoV-2 vaccine. To our knowledge, this is the first report of biopsy-confirmed, delayed inflammatory myositis after administration of an mRNA-1273 SARS-CoV-2 vaccine booster.

Keywords: COVID-19; SARS-CoV-2; mRNA vaccine; myositis.